{"groups":[{"description":"Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Triapine and Fludarabine Phosphate"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Once patient consented to treatment, treatment began shortly there after.","recruitmentDetails":"Patient's presenting for treatment of a myeloproliferative disease were considered for participation."}